Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2025 02:45 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: FOURTH QUARTER & FULL YEAR 2024 FINANCIAL REPORT

HBC achieved full-year sales revenue of NOK 256.8 million, a 35% increase from 2023, with strong momentum in higher-margin B2B human nutrition. The shift towards premium products, particularly CalGo®...
December 12, 2024 09:07 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC") has today purchased 700,000 shares in HBC at an average price of NOK 1.202837 per share. As a...
December 05, 2024 03:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: Commences the project for a second hydrolysis plant in Norway to triple capacity

Hofseth BioCare ASA ("HBC" or the "Company", and together with its consolidated subsidiaries, the "Group") is pleased to announce a Board resolution to start a project to build a second hydrolysis...
November 08, 2024 02:15 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: THIRD QUARTER 2024 FINANCIAL REPORT

HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first nine months. The operating loss (EBITDA) for the quarter was NOK -21.0m (-16.2m) and NOK...
October 22, 2024 04:56 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: CFO RESIGNATION

Christel Elise Kanli has decided to step down as Chief Financial Officer (CFO) of Hofseth BioCare ASA (“HBC”) to pursue opportunities outside of the company. "I would like to thank Christel for her...
October 08, 2024 02:45 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT

Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel...
August 23, 2024 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT

HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half year. Adjusted for the sale of assets in the second quarter, sales revenues were NOK...
August 14, 2024 07:09 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY

Ålesund, Norway, 14 August, 2024 - Hofseth BioCare (HBC), a leader in science-led marine nutrition, proudly announces compelling new findings from a recent study on the benefits of its enzymatically...
July 02, 2024 03:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.

Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, today announces the decision to transfer its eosinophil-targeting drug candidate...
June 11, 2024 03:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd (Lithy) as an additional distributor in China. Shanghai-based Lithy has entered into...